Phase 2 clinical trial of Imprime PGG and bevacizumab achieved meaningful reductions in tumour burden

The combination of the investigational cancer immunotherapy Imprime PGG and the monoclonal antibody bevacizumab achieved additional meaningful reductions in tumour burden during the maintenance phase of Biothera’s recent Phase 2 clinical trial in non-small cell lung cancer (NSCLC).

Biothera conducted a randomised Phase 2 clinical study in non-squamous NSCLC in which Imprime PGG was administered in combination with bevacizumab and platinum-based doublet chemotherapy. After four to six cycles of treatment, patients received maintenance therapy of bevacizumab with or without Imprime PGG. Further meaningful reductions in tumour burden (>10mm) were observed in 6 (20%) of patients in the Imprime PGG group, but not in the control group.

Imprime PGG results show potential for chemotherapy-free maintenance therapy

“Patients receiving the combination of Imprime PGG and bevacizumab experienced further reduction in their tumour burden than with bevacizumab therapy alone,” said Ada Braun, M.D., Ph.D., Biothera Chief Medical Officer. “These results highlight the efficacy of Imprime PGG and show the potential for continued tumour regressions on chemotherapy-free maintenance therapy for some patients.”

The results of the Biothera NSCLC study evaluating the addition of Imprime PGG to bevacizumab and carboplatin/paclitaxel versus bevacizumab and chemotherapy alone were highly promising. In comparing the treatment and control groups, the objective response rate was 60.4% versus 43.5%, duration of response was 10.3 months versus 5.6 months and median overall survival was 16.1 months versus 11.6 months.

Biothera will present the data at the European Lung Cancer Conference being held in Geneva Switzerland.

For more information about Biothera, please visit www.biothera.com/pharma.